Aclaris Therapeutics Inc Receives a Buy from Cantor Fitzgerald


Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Aclaris Therapeutics Inc (NASDAQ: ACRS) today and set a price target of $50. The company’s shares opened today at $18.37.

Chen said:

“Positives from the quarter: 1) On 1/08/18 ACRS announced positive results from its two Phase 2 clinical trials (WART-202 and 45% topical solution, for the treatment of common warts.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -11.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Spero Therapeutics Inc, and Theravance Biopharma.

Aclaris Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $45.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $30.08 and a one-year low of $16.01. Currently, Aclaris Therapeutics Inc has an average volume of 257.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in identifying, developing and commercializing novel drugs to address unmet needs in dermatology. It also pursues the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications. The company was founded by Neal S.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts